Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 3/20 | 0.57 |
| ▸ | MAPT | P10636 | 2/20 | 0.57 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 4/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.56 |
| ▸ | NPC1 | O15118 | 2/20 | 0.56 |
| ▸ | THRB | P10828 | 3/20 | 0.54 |
| ▸ | STAT3 | P40763 | 1/20 | 0.52 |
| ▸ | STAT1 | P42224 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | CDH1 | P12830 | 1/20 | 0.48 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.48 |
| ▸ | TCF7L2 | Q9NQB0 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | MME | P08473 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12756517 | 0.90 | KMT2A (0.61) | TP53MAPTMEN1KMT2ANPC1 | |
| SCHEMBL1490373 | 0.81 | KMT2A (0.52) | TP53MAPTRXFP1MEN1KMT2A | |
| SCHEMBL12756545 | 0.81 | ANO1 (0.49) | TP53MAPTRXFP1MEN1KMT2A | |
| SCHEMBL12829995 | 0.81 | NPC1 (0.54) | MAPTMEN1KMT2ANPC1TDP1 | |
| SCHEMBL1952407 | 0.80 | TP53 (0.75) | TP53MAPTMEN1KMT2A | |
| SCHEMBL12756531 | 0.79 | GRM5 (0.52) | MAPTMEN1KMT2AMME | |
| SCHEMBL12830429 | 0.79 | ANO1 (0.42) | MAPTRXFP1MEN1KMT2ATDP1 | |
| SCHEMBL12830148 | 0.79 | ANO1 (0.41) | TP53MAPTMEN1KMT2ANPC1 | |
| SCHEMBL15480667 | 0.79 | MAPT (0.54) | TP53MAPTRXFP1MEN1KMT2A | |
| SCHEMBL1490509 | 0.79 | KMT2A (0.55) | TP53MAPTRXFP1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140051711-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA INC. (US) | 2014-02-20 | — | — | US | disclosed |
| US-20140051711-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA INC. (US) | 2014-02-20 | — | — | US | disclosed |
| WO-2011034962-A2 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA INC. (US) | 2011-03-24 | — | — | WO | disclosed |
| US-20110065724-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA, INC. (US) | 2011-03-17 | — | — | US | disclosed |
| US-20110065724-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA, INC. (US) | 2011-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140051711-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | ORAI1, SARAF, RYR2 | TP53 2681/4885MAPT 1478/4885RXFP1 2109/4885 |
| US-20110065724-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | ORAI1, SARAF, RYR2 | TP53 2681/4885MAPT 1478/4885RXFP1 2109/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.